Abstract
The neuropeptide (des-tyrosine 1)-γ-endorphin (DTγE; β-LPH 62–77) was given to 10 schizophrenic patients who had been free of neuroleptic medication for at least 3 weeks. DTγE was injected intramuscularly in a dose of 1 mg daily for 10 days following a double-blind placebo-controlled crossover design. In 4 of the 10 patients a pronounced antipsychotic effect was observed; in 3 a temporary or slight reduction of psychotic symptoms occured; and in 3 no response was noted. DTγE led to decreased plasma levels of prolactin and in some patients to increased concentrations of homovanillic acid in cerebrospinal fluid (CSF). Neither plasma levels of growth hormone and cortisol nor CSF concentrations of 5- hydroxyindoleacetic acid were affected by DTγE. These data confirm that DTγE has antipsychotic properties in a number of schizophrenic patients and suggest an interaction between DTγE and central dopaminergic systems.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
